Hosted on MSN1mon
SCG’s HBV T-cell therapy shows promise in Phase I trialSCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101. The therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback